Documentation gap analysis in preparation for FDA scientific advice meeting
Challenge:
Our client was committed to applying a deep understanding of axon regeneration and neuronal signaling pathways to transform the lives of patients afflicted with neurotrauma or neurovascular disorders; its lead product was in development for acute cervical spinal cord injury. The client required FDA advice on its intended Phase II trial design and other non-clinical aspects on the program and therefore required support in preparing for a Type B meeting with the FDA's Division of Neurology Products.
Solution:
There were several key areas on which the client required FDA response to, these included:- Clinical: To reach agreement with the Agency regarding the design of a Phase IIb trial
- Chemistry, Manufacturing, and Controls: To discuss plans to re-derive the product Master Cell Bank following discovery of the use of animal-derived products as well as minor proposed modifications to the downstream processing
- Nonclinical: To discuss the whether the nonclinical toxicology package is sufficient to support approval.
- Introductory and Administrative Information Section
- Brief Background Information Section
- Specific Questions for Discussion Section
- Overview of Development Program To Date
- Proposed Phase IIb Trial Protocol
- Proposed Investigator’s Brochure
- Proposed Data Monitoring Committee (DMC) Charter
Related Case Studies
Explore similar engagements and see how we've helped other clients achieve their goals.
Product Development
Gene therapy preclinical, CMC, and regulatory strategy
Challenge: An early-stage biotechnology startup company reached out to Alacrita for critical support of its two lead AAV-delivered gene therapy programs. As a virtual company, the...
Product Development
Interim chief medical officer for antiviral drug company
Challenge A European company developing novel antiviral drugs urgently needed an experienced pharmaceutical physician to work as an interim CMO, as the predecessor was about to...
Product Development
Preclinical development support for a gene therapy
Challenge: A biotech company developing novel gene therapy approaches for in vivo cell trans-differentiation required an AAV gene therapy expert to serve on a scientific advisory...
Product Development
Primary market research and patient segmentation mapping in myelofibrosis
Challenge: A venture-backed US biotech company was developing a preclinical biologic for haematological indications and wished to quantify the commercial opportunity for the...
Interested in Learning More?
Contact us to discuss how we can support your project with similar expertise.